Substance,Type of TRV,TRV Value,Study Details,"Threshold/
Non-threshold
Endpoint",TRV Derivation Method,"Critical
Effect(s)","Carcinogenicity
Classification",Source
"Chromium,
hexavalent",Oral TDI,"2.2E-03
mg/kg -day
BW","Study Type: chronic
Species: male and female B6C3F1 mice
Mode of Administration: oral
(drinking water)
Exposure Regime: Male mice received 0,
14.3, 28.6, 85.7, or 257.4 mg sodium
dichromate dehydrate (SSD)/L (equivalent
to 0, 5, 10, 30, and 90 mg Cr (VI)/L or 0,
0.4, 0.9, 2.4 and 5.9 mg Cr (VI)/kg -day
BW
respectively). Female mice received 0,
14.3, 57.3, 172, or 516 mg sodium
dichromate dihydrate/L (equivalent to 0,
5, 20, 60, and 180 mg Cr (VI)/L or 0, 0.4,
1.4, 3.1, and 8.7 mg Cr (VI)/kg -day).
BW
Duration: 2 years
Uncertainty Factors: 25 (10 for
intraspecies variability and 2.5 for
pharmacodynamic interspecies
differences)","BMDL =
01
0.67 mg Cr(VI)/
kg -day
BW","PBPK model used to
convert mouse BMDL into
01
a human equivalent dose of
0.054 mg Cr (VI)/ kg -day
BW
TDI =
human equivalent dose/UF","Gastrointestinal
toxicity
(diffuse epithelial
hyperplasia of the
small intestine)","CEPA: Group I
carcinogenic
to humans
(EC and HC, 1994c)
IARC: Group 1
carcinogenic
to humans
(IARC, 2012a)
US EPA IRIS:
Group A
inhalation route:
carcinogenic
to humans
(US EPA, 1998d);
Group D
oral route:
not classifiable
as to human
carcinogenicity
(US EPA, 1998d)","HC, 2016b
(based on
NTP, 2008
Stout et al., 2009;
Thompson et al.,
2014; Summit
Toxicology, 2014)"
"Chromium,
hexavalent",Inhalation TC,"1.0E-04
mg/m3","Study Type: subchronic
Species: male Wistar rats
Mode of Administration: inhalation
(whole body exposure chambers)
Exposure Regime: sodium
dichromate (chromium particulates),
0.05-0.4 mg Cr (VI)/m3 for 22 hours/day,
7 days/week
Duration: 30 to 90 days
Uncertainty Factors: 300 (10 for use
of a subchronic study, 10 for intraspecies
variability, and 3 for pharmacodynamic
interspecies differences)","BMC =
10
0.034 mg Cr (VI)/m3","BMC selected as POD
10
and adjusted for
continuous exposure
+
Animal to human
conversion based on
regional deposited dose
ratio for particulates
TC for Cr (VI) =
BMC /UF
10","Respiratory
tract toxicity
(increased albumin
and lactate
dehydrogenase in
bronchioalveolar
lavage fluid,
reflecting initial
injury and chronic
inflammation)",,"US EPA, 1998d
(based on
Glaser et al., 1990
and Malsch et al.,
1994)"
"Chromium,
hexavalent",Inhalation UR,"7.6E+01
(mg/m3)–1","Study Type: epidemiological
(occupational)
Species: humans (adult men)
Mode of Exposure: inhalation
Exposure Concentrations: N/A
Duration: at least 1 year, up to 8 years
Uncertainty Factors: N/A","TC (5% tumourigenic
05
concentration) =
0.66 µg/m3","Inhalation UR =
0.05/TC
05
where 0.05 = 5% extra
cancer risk","Cancer
(lung)",,"HC, 1996
(based on
Mancuso, 1975)"
